t
SkinBioTherapeutics plc confirmed the appointment of Simon Hewitson as an Executive Director on the Board and Chief Operating Officer of the Group, effective 28 April 2025. Mr. Hewitson, aged 49, holds no shares in SkinBioTherapeutics and previously held directorships at Northumbrian Ice Cream Company Limited and Polar Krush Group Limited within the last five years.
| Date | 28 Apr 2025 |
| Time | 07:00:08 |
| Category | Board changes |
| ID | 3205G |
SkinBioTherapeutics plc
("SkinBioTherapeutics" or "the Company")
Board Appointment Confirmation
28 April 2025 - Further to the Group's announcement on 24 April 2025, the Board of Directors of SkinBioTherapeutics, (AIM: SBTX), a life science company focused on skin health, now confirms the appointment of Simon Hewitson as an Executive Director on the Board and Chief Operating Officer of the Group, with immediate effect.
The following information is disclosed pursuant to rule 17 and Schedule Two paragraph (g) of the AIM Rules for Companies:
|
Full name: |
Simon Jonathan Hewitson |
|
Age: |
49 |
|
Shareholding in SkinBioTherapeutics: |
None |
|
Current directorships held: |
None |
|
Directorships held in the previous 5 years: |
Northumbrian Ice Cream Company Limited |
-Ends-
For more information please contact:
|
SkinBioTherapeutics plc Martin Hunt, Chair Stuart J. Ashman, CEO |
+44 (0) 191 495 7325
|
|
Cavendish Capital Markets Limited (Nominated Adviser & Broker) Giles Balleny, Dan Hodkinson (Corporate Finance) Charlie Combe (Broking) Dale Bellis (Sales) |
+44 (0) 20 7220 0500
|
|
Vigo Consulting (financial press) Rozi Morris |
+44 (0) 20 7390 0230
|
Notes to Editors
About SkinBioTherapeutics plc
SkinBioTherapeutics is a life science company focused on skin health. The Group's proprietary platform technology, SkinBiotix®, is based upon discoveries made by the translational dermatology team at the University of Manchester.
The Group's foundation business is targeting the skin healthcare market via five pillars, the most advanced of which are cosmetic skincare (SkinBiotix) and food supplements to modulate the immune system by harnessing the gut-skin axis (AxisBiotix). The cosmetic pillar has a partnership with Croda plc and the SkinBiotix active ingredient, Zenakine™ was launched in April 2025. The Group's first in-house product, AxisBiotix-Ps™, is a food supplement to address the symptoms of mild to moderate psoriasis.
The Group is also acting as a consolidator and is making acquisitions in complementary areas such as skin care and cosmetic applications, that also bring new distribution and geographical platforms, and manufacturing capabilities through which it can funnel its in-house pillar products.
The Company listed on AIM in April 2017 and is based in Newcastle, UK. For more information, visit: www.skinbiotherapeutics.com.